Company intelligence / Profile preview

Modulim

Irvine, California, United Statesmodulim.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company’s Clarifi™ Imaging System has received FDA clearance for non-invasive measurement of tissue oxygenation in patients at risk for circulatory compromise. Early clinical data suggest the technology enables proactive identification of patients at risk for diabetic foot ulcers and vascular complications. The system supports improved patient outcomes by enabling timely interventions to prevent amputations.

Therapeutic areas: EndocrinologyCardiovascular
Modalities: DeviceNon-pharmacological therapyData analytics platform (for clinical decision support)
Industry: Medical Imaging

Partnerships

Fresenius Medical Care Ventures GmbH (strategic investor)Pangaea VenturesMitsubishi UFJ Capital Co. Ltd.Grey Sky Venture Partners

Beyond the preview

Go deeper on Modulim.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Modulim.

Explore the full profile